|
Chemotherapy-tumor
Citations 1-10 of 72 total displayed.
|
Most recent content
(24 Nov 2009):
|
- ARTICLES
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide
- H. J. Dubbink, W. Taal, R. van Marion, J. M. Kros, I. van Heuvel, J. E. Bromberg, B. A. Zonnenberg, C.B.L. Zonnenberg, T. J. Postma, J. M.M. Gijtenbeek, W. Boogerd, F. H. Groenendijk, P. A.E. Sillevis Smitt, W. N.M. Dinjens, and M. J. van den Bent
Neurology 2009; 73: 1792-1795.
[Abstract]
[Full text]
[PDF]
|
Past content
(since Jan 2001):
|
- ARTICLES
Bevacizumab for recurrent ependymoma
- R. M. Green, T. F. Cloughesy, R. Stupp, L. M. DeAngelis, E. A. Woyshner, D. E. Ney, and A. B. Lassman
Neurology 2009; 73: 1677-1680.
[Abstract]
[Full text]
[PDF]
- ARTICLES
Supratentorial low-grade gliomas in older patients
- G. Kaloshi, D. Psimaras, K. Mokhtari, C. Dehais, C. Houillier, Y. Marie, F. Laigle-Donadey, S. Taillibert, R. Guillevin, N. Martin-Duverneuil, M. Sanson, K. Hoang-Xuan, and J.-Y. Delattre
Neurology first published on November 11, 2009 as doi: WNL.0b013e3181c6781e.
[Abstract]
Rapid PDF
- EDITORIALS
Equal care for the elderly with low-grade gliomas?
- Amy Pruitt and John W. Henson
Neurology first published on November 11, 2009 as doi: WNL.0b013e3181c67882.
Rapid PDF
- ARTICLES
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
- F. M. Iwamoto, L. E. Abrey, K. Beal, P. H. Gutin, M. K. Rosenblum, V. E. Reuter, L. M. DeAngelis, and A. B. Lassman
Neurology 2009; 73: 1200-1206.
[Abstract]
[Full text]
[PDF]
- CLINICAL/SCIENTIFIC NOTES
MYELOMA-ASSOCIATED POLYNEUROPATHY RESPONDING TO LENALIDOMIDE
- Robert Layzer and Jeffrey Wolf
Neurology 2009; 73: 812-813.
[Full text]
[PDF]
- ARTICLES
Gray matter involvement predicts chemosensitivity and prognosis in gliomatosis cerebri
- G. Kaloshi, R. Guillevin, N. Martin-Duverneuil, F. Laigle-Donadey, D. Psimaras, Y. Marie, K. Mokhtari, K. Hoang-Xuan, J. -Y. Delattre, and M. Sanson
Neurology 2009; 73: 445-449.
[Abstract]
[Full text]
[PDF]
- ARTICLES
Bevacizumab and irinotecan for recurrent oligodendroglial tumors
- S. Taillibert, L. A. Vincent, B. Granger, Y. Marie, C. Carpentier, R. Guillevin, A. Bellanger, K. Mokhtari, A. Rousseau, D. Psimaras, C. Dehais, M. Sierra del Rio, Y. Meng, F. Laigle-Donadey, K. Hoang-Xuan, M. Sanson, and J. Y. Delattre
Neurology 2009; 72: 1601-1606.
[Abstract]
[Full text]
[PDF]
- ARTICLES
Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience
- P. L. Nghiemphu, W. Liu, Y. Lee, T. Than, C. Graham, A. Lai, R. M. Green, W. B. Pope, L. M. Liau, P. S. Mischel, S. F. Nelson, R. Elashoff, and T. F. Cloughesy
Neurology 2009; 72: 1217-1222.
[Abstract]
[Full text]
[PDF]
- SPECIAL ARTICLES: INVITED ARTICLES
Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas
- Warren P. Mason and J. Gregory Cairncross
Neurology 2008; 71: 365-373.
[Abstract]
[Full text]
[PDF]
|
|
